Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254046 · ClinicalTrials.gov registry record · Phase 3
TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
A Phase 3 study, sponsored by Tibotec Pharmaceuticals, Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 616
- Enrollment target
NCT00254046: Completed Phase 3 study, sponsored by Tibotec Pharmaceuticals, Ireland.
NCT00254046 is a Phase 3 study that has completed, run by Tibotec Pharmaceuticals, Ireland. The registered enrollment target is 616 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254046, a Phase 3 study, has completed, sponsored by Tibotec Pharmaceuticals, Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 616 participants
- Enrollment target
Study Summary
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medication is safe to be used.
Interventions
- DRUG Placebo
- DRUG TMC125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
What the finished NCT00254046 record still lists
NCT00254046 is an interventional study that assigns participants to a tested intervention. The registered 616 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00254046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00254046 about?
NCT00254046 is a clinical study titled "TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.". The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medica...
What is the current status of trial NCT00254046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 616 participants. The study started on 2005-11. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00254046?
The interventions under investigation include: Placebo (DRUG), TMC125 (DRUG).
Who is sponsoring clinical trial NCT00254046?
This trial is sponsored by Tibotec Pharmaceuticals, Ireland, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00254046's enrollment target sits among peer trials
616 593rd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
- NCT06105957 · 616 participants · NA
Optimal Digital Weight Loss Treatment for Rural Individuals
- NCT06162221 · 616 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia